Coherus Oncology (CHRS) valuation against sector peers: P/B 1.9, P/S 2.3.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Metric	CHRS	Sector median	vs median
P/E	—	29.1 · n=156	—
P/B	1.9	3.8 · n=306	49% below
P/S	2.3	4.1 · n=299	44% below
EV/EBIT	—	25.9 · n=143	—
Free-cash-flow yield	—	1.5% · n=288	—
Dividend yield	0.00%	0.00% · n=361	—
Return on equity	−146.3%	−2.7% · n=305	—
Return on invested capital	—	0.4% · n=278	—
Gross margin	68.9%	63.1% · n=204	9% above
Net debt / EBITDA	—	1.24 · n=148	—

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Sector peers

The largest companies of the same sector and region.

Instrument	P/E	P/B	EV/EBIT	Free-cash-flow yield	Dividend yield	Smart Score
LLYEli Lilly & Co	46.6	31.9	—	1.5%	0.6%	6/10
JNJJohnson & Johnson	40.7	8.0	—	3.1%	1.9%	8/10
ABBVAbbVie	49.5	—	27.3	3.7%	3.0%	6/10
MRKMerck	147.7	8.1	—	4.1%	2.3%	8/10
UNHUnitedHealth	22.3	3.4	17.0	6.4%	2.3%	10/10
TMOThermo Fisher Scientific	35.5	4.6	33.8	3.0%	0.3%	9/10
AMGNAmgen	26.5	17.3	23.0	3.8%	2.2%	8/10
GILDGilead Sciences	—	15.9	—	6.6%	1.9%	4/10
ABTAbbott	41.9	3.9	33.7	3.4%	2.7%	6/10
PFEPfizer	42.2	1.9	—	6.9%	7.2%	1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Jun 2026 · filed 05 Aug 2026

Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.

Cookie settings